We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Glucose Monitoring System Designed for Accuracy

By LabMedica International staff writers
Posted on 29 Jul 2013
Recently more attention has been drawn to the accuracy requirements for blood glucose monitoring systems (BGMS) for home use as well as those for hospital use.

Tighter accuracy criteria are being introduced internationally for BGMS and therefore newer systems need to be evaluated for point-of-care testing (POCT) of blood glucose, a valuable biomarker for the management of patients with diabetes and other conditions. More...


Collaborating scientists from three different institutions and the commercial manufacturer evaluated a BGMS in a multicenter study for precision, interference, and system accuracy using 503 blood samples from capillary, venous, and arterial sources. Included in the study was interference testing, both hematocrit and other substances, and accuracy evaluations. The institutes were the Rainier Clinical Research Center (Renton, WA, USA), the Duke University Medical Center (Durham, NC, USA), and MassResearch LLC (Waltham, MA, USA).

The FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System (Abbott Diabetes Care; Alameda, CA, USA) is designed to simplify POCT for healthcare professionals, providing features that enhance the reliability of the testing process and support compliance with POCT policies. The FreeStyle Precision Pro blood glucose-test strip is individually sealed, and each test strip contains three electrodes, working, reference, and fill trigger. The circuit between the fill trigger and the reference electrodes must be detected by the meter before the test will start. The minimum sample volume required is 0.6 μL and the test time is five seconds.

The FreeStyle Precision Pro system demonstrated acceptable precision, no interference across a hematocrit range of 15% to 65%, and, except for xylose, no interference from 24 of 25 potentially interfering substances. From the individual results of various blood sample types, 97.3% to 98.9% agreed within ±12 mg/dL of the laboratory analyzer values at glucose concentrations less than 100 mg/dL and within ±12.5% of the laboratory analyzer values at glucose concentrations equal to or greater than 100 mg/dL.

The authors concluded that the FreeStyle Precision Pro system makes more measurements and uses more signals from the glucose electrochemical reaction to increase accuracy; it also performs more integrity checks to detect potential errors during each glucose test. The study was published on June 5, 2013, in the journal Clinica Chimica Acta.

Related Links:

Rainier Clinical Research Center
Duke University Medical Center
Abbott Diabetes Care



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Automated Immunoassay Analyzer
SuperFlex™
New
Silver Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.